Abaloparatide — Complete Research Guide (2026)

Last updated 2026-06-30

What is Abaloparatide?

Abaloparatide (marketed as Tymlos in the US and Eladynos in the EU) is a synthetic analog of parathyroid hormone-related protein (PTHrP) approved by the FDA for postmenopausal women with osteoporosis at high risk of fracture, later extended to men with osteoporosis, and approved by the EMA for postmenopausal osteoporosis.

The evidence level is high: approval is based on the pivotal phase 3 ACTIVE randomized, placebo-controlled human trial and its ACTIVExtend follow-on.

How does Abaloparatide work?

Abaloparatide is an anabolic (bone-building) agent that selectively activates the PTH-1 receptor, favouring the transient RG conformation to stimulate osteoblast-driven new bone formation more than bone resorption.

The net effect is increased bone mineral density and improved bone microarchitecture, lowering fracture risk.

What does the research say about Abaloparatide?

• In postmenopausal osteoporosis, abaloparatide significantly reduced the risk of new vertebral and nonvertebral fractures versus placebo (ACTIVE). ^[1]
• Sequential abaloparatide followed by alendronate sustained fracture-risk reduction and bone density gains over 43 months (ACTIVExtend). ^[2]
• Abaloparatide produced higher bone-mineral-density response rates than placebo or teriparatide in the ACTIVE trial. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial — Miller PD et al., JAMA 2016. (Phase 3 randomized placebo-controlled clinical trial (ACTIVE))
• [2] Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial — Cosman F et al., Mayo Clinic Proceedings 2017. (Phase 3 extension trial (ACTIVExtend))
• [3] Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial — Miller PD et al., Bone 2019. (Phase 3 trial analysis (ACTIVE))
• [4] Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend — Cosman F et al., Journal of Bone and Mineral Research 2023. (Post hoc analysis of phase 3 trials)
• [5] Abaloparatide: A review of preclinical and clinical studies — Brent MB, European Journal of Pharmacology 2021. (Narrative review (covers both preclinical/animal and human clinical data))

Dosing context

This is context only and not dosing advice: abaloparatide is given as a once-daily subcutaneous injection (80 micrograms) from a prefilled pen, typically self-administered after training, with the first doses taken where the patient can sit or lie down due to possible orthostatic hypotension.

It is a prescription anabolic osteoporosis drug used for a defined treatment course under medical supervision.

Side effects & safety profile

As a class of PTH/PTHrP anabolic agents, abaloparatide has been linked to a rodent osteosarcoma (malignant bone tumour) signal observed when rats were given high, lifelong doses, and it historically carried a boxed warning and a 2-year cumulative-use limit on that basis; labeling for this class has evolved as long-term human data accrued, so the current prescribing information should be consulted for the exact warning and treatment-duration language.

Common adverse effects include orthostatic hypotension and dizziness (especially after the first doses), palpitations, nausea, headache, injection-site reactions, and hypercalciuria or hypercalcaemia.

It is contraindicated where there is baseline increased osteosarcoma risk (for example Paget's disease of bone, prior skeletal radiation, or unexplained elevated alkaline phosphatase), and is a prescription anabolic drug used for a defined course under medical supervision.

Stacking & combinations

Anabolic therapy is typically followed sequentially by an antiresorptive agent such as alendronate to preserve the bone gains, rather than combined with other peptides for enhancement.

Finding Abaloparatide vendors

User reviews

Frequently asked questions

References

1. [1] Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial — Miller PD et al., JAMA 2016. PMID: 27533157. View sourceStudy: Phase 3 randomized placebo-controlled clinical trial (ACTIVE)Abaloparatide significantly reduced new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.
2. [2] Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial — Cosman F et al., Mayo Clinic Proceedings 2017. PMID: 28160873. View sourceStudy: Phase 3 extension trial (ACTIVExtend)Abaloparatide followed by alendronate sustained fracture-risk reduction and bone density gains through 43 months.
3. [3] Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial — Miller PD et al., Bone 2019. PMID: 30359763. View sourceStudy: Phase 3 trial analysis (ACTIVE)A greater proportion of abaloparatide-treated patients achieved meaningful BMD gains than with placebo or teriparatide.
4. [4] Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend — Cosman F et al., Journal of Bone and Mineral Research 2023. PMID: 36588166. View sourceStudy: Post hoc analysis of phase 3 trialsAbaloparatide improved trabecular bone score, indicating better bone microarchitecture beyond density alone.
5. [5] Abaloparatide: A review of preclinical and clinical studies — Brent MB, European Journal of Pharmacology 2021. PMID: 34364879. View sourceStudy: Narrative review (covers both preclinical/animal and human clinical data)Summarizes abaloparatide's anabolic mechanism and the preclinical and clinical evidence supporting its fracture-risk reduction.